Australia markets open in 9 hours 44 minutes

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
108.80-1.70 (-1.54%)
At close: 4:02PM EST

107.55 -1.25 (-1.15%)
Before hours: 8:16AM EST

Full screen
Trade prices are not sourced from all markets
Previous close110.50
Open111.30
Bid0.00 x 900
Ask0.00 x 800
Day's range108.56 - 111.30
52-week range62.55 - 113.41
Volume5,408,216
Avg. volume8,201,367
Market cap192.014B
Beta (5Y monthly)0.82
PE ratio (TTM)23.80
EPS (TTM)4.57
Earnings date03 Feb 2021
Forward dividend & yield5.20 (4.78%)
Ex-dividend date14 Jan 2021
1y target est117.48
  • AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
    Zacks

    AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

    AbbVie (ABBV) closed at $108.80 in the latest trading session, marking a -1.54% move from the prior day.

  • CoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite
    PR Newswire

    CoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite

    Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of CoolSculpting® Elite, its next generation fat reduction system with applicators designed to complement the body's natural curves. CoolSculpting® Elite harnesses proven CoolSculpting® technology to target, freeze, and eliminate treated fat cells. CoolSculpting® Elite is FDA cleared to treat visible fat bulges in nine areas of the body including the thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), upper arm, and the submental and submandibular areas.

  • 2 Stocks I'll Hold Forever
    Motley Fool

    2 Stocks I'll Hold Forever

    As a major pharma company, AbbVie (NYSE: ABBV) delivers for its investors by developing and commercializing new drugs, like its best-selling arthritis treatment Humira. There's two reasons AbbVie is worth holding forever: its skill with drug development, and its generous dividend. Like many other pharma companies, AbbVie maximizes the revenue that it gets from each of its drug development projects by investigating their usefulness for multiple illnesses.